Oriola lowers 2026 outlook after Swedish supply chain disruptions
Pharmaceutical distributor Oriola has lowered its outlook for 2026 and no longer expects adjusted EBITDA to increase from last year. The company now expects adjusted EBITDA to be at the same level as or higher than in 2025, when it was EUR 35.1 million.
November 12, 2026
According to Oriola, the fourth-quarter result will not be enough to reach the previous guidance because of higher-than-expected operating expenses in October, mainly caused by disruptions in its Swedish supply chain operations.
The revised outlook reflects expected sales growth in both of Oriola’s segments and the positive impact of new distribution partnerships in the fourth quarter. The company publishes its full-year results on February 23, 2027.
Preparedness for a new era – Clear roles and Nordic collaboration
In December last year, Sweden’s National Board of Health and Welfare and the Swedish Civil Contingencies Agency concluded that the country’s pharmaceutical stockpiles are insufficient to cope with a crisis or war. That is a serious conclusion. Their report outlines 130 measures to address this, 40 of which are considered to be high priority. But the key question is: how will the stockpiling work in practice?
Published: November 12, 2026
